{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Heudel P"],"pubmed_abstract":["<h4>Importance</h4>Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy.<h4>Objective</h4>To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor-positive recurrent or metastatic endometrial cancer.<h4>Design, settings, and participants</h4>The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor-positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a Si"],"journal":["JAMA oncology"],"pagination":["1001-1009"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9100474"],"repository":["biostudies-literature"],"pubmed_title":["Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial."],"pmcid":["PMC9100474"],"pubmed_authors":["Marcel V","Arnaud A","Pautier P","Diaz JJ","Fabbro M","Heudel P","Chevalier-Place A","Treilleux I","Bazan F","Dalban C","Augereau P","Frenel JS","Joly F","Ray-Coquard I","Chakiba C","Perol D","Abdeddaim C","You B","Garin G","Lancry-Lecomte L"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.","description":"<h4>Importance</h4>Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy.<h4>Objective</h4>To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor-positive recurrent or metastatic endometrial cancer.<h4>Design, settings, and participants</h4>The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor-positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a Si","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-05-09T22:15:43.808Z","creation":"2024-11-13T01:35:14.598Z"},"accession":"S-EPMC9100474","cross_references":{"pubmed":["35551299"],"doi":["10.1001/jamaoncol.2022.1047"]}}